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A B S T R A C T
The ﬁeld of therapeutics is evolving to include a greater proportion of higher molecular weight,
hydrophilic biological compounds. To cater for this new era in healthcare the concomitant development
of appropriate drug delivery systems is essential to aid cellular permeation. In this manuscript we present
the synthesis, characterisation and biological evaluation of a charge neutral polymersome (Ps) based
drug delivery system (DDS) using an amphiphilic pegylated random copolymer. A detailed dynamic light
scattering study revealed that the hydrodynamic diameter of the Ps can be tailored to a speciﬁc size
simply by varying the quantities and ratios used during the preparation step. The zeta potential of this
new drug delivery system was determined to be 0.095  0.037 mV, the encapsulation efﬁciency of
Fitc-CM-Dextran (4 KDa) was 70%, the uptake of Fitc-CM-Dextran by Hela cells was increased 4-fold
when encapsulated within the polymersomal system. The facile preparation, high loading capacity and
size tuneable nature of this Ps renders it a promising alternative to the ever growing array of currently
available Ps.
ã 2015 Elsevier B.V. All rights reserved.
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Medicine has evolved from the ‘one size ﬁts all’ approach to
drug development with thanks in part to the Human Genome
Project (HGP) that was completed more than a decade ago
(Consortium, 2001). Since the completion of this landmark
discovery there has been a pervasive increase and exploration of
personalised medicine. The therapeutic use of siRNAs, proteins and
enzymes has allowed for a revolution in healthcare regimes (Guo
et al., 2010). In order to reach its full potential, it is essential that
these therapeutics can be delivered to the required site of action.
These large, hydrophilic and often highly charged compounds
come with their own problems regarding cell permeability and
drug delivery. One method that has proven successful for the
delivery of these biological compounds is the use of nanoparticles
(NPs). NPs are colloidal nano-sized particles with a diameter
ranging between 1 and 1000 nm whereby the drug of interest can
either be encapsulated, absorbed or dispersed within them (Allen
and Cullis, 2013; Mazak and Noszal, 2014; Vonarbourg et al., 2006).
Nanoparticulate systems show promise as active vectors due to* Corresponding author. Tel.: +44 28 70 123510; fax: +44 28 70 123518.
E-mail address: b.callan@ulster.ac.uk (B. Callan).
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0378-5173/ã 2015 Elsevier B.V. All rights reserved.their capacity to release drugs, subcellular size allowing for
relatively high intracellular uptake, the potential to provide
improved stability of active substances and their biocompatibility
with tissues and cells (Mora-Huertas et al., 2010). A wide variety of
nanoparticles composed of a range of materials have been
developed, resulting in delivery systems that vary in their
physicochemical properties and thus their applications (Burt
and Letchford, 2007). Current nanoparticulate drug delivery
systems being investigated include liposomes (Qu et al., 2014),
micelles (Torchilin, 2007), nanospheres (Yu et al., 2014), nano-
capsules (Musyanovych and Landfester, 2014), niosomes (Kazi
et al., 2010) and polymersomes (Wang et al., 2014; Discher et al.,
1999; Levine et al., 2008; Ahmed et al., 2006) among others.
Currently there are several liposomal based drug delivery
systems approved by the U.S. food and drug administration.
Although these formulations show enhanced delivery and efﬁcacy
of therapy, they still have been shown to render some serious side
effects (Nahire et al., 2014), partially due to their surface charges
(Barenholz, 2012). To that end we have developed a polymersomal
based drug delivery system that is charge neutral and whose
hydrodynamic diameter can be tailored according to the desired
size of the nanoparticle required.
Polymersomes are polymeric capsules with a bilayered
membrane comprised of synthetic amphiphilic block copolymers,
Fig. 1. Schematic representation of polymersome formed from amphiphilic co polymer.
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liposome in that they are both composed of a bilayer of
amphiphiles enclosing an aqueous compartment (Brinkhuis
et al., 2011). However, the difference between these two vehicles
is that most liposomes are naturally occurring phospholipids and
as such have both a strong negative charge and lower molecular
weight than the synthetic polymeric alternatives. This enhanced
ability to speciﬁcally tailor Ps formulation methods, physicochem-
ical properties, release mechanisms and even targeting chemis-
tries make polymersomes an ideal platform for the encapsulation
of a broad range of therapeutic molecules (Christian et al., 2009).
The incorporation of poly(ethylene glycol) (PEG) as the hydrophilic
component in many of these polymersomal NPs is commonplace
as it has been shown to reduce the reticuloendothelial system
(RES) uptake as well as to increase the circulation time of the NP
(Jokerst et al., 2011). Here we present for the ﬁrst time a neutral,
size tuneable Ps prepared from a co-polymer we have previously
shown to self-assemble and form a micellar structure capable of
encapsulating hydrophobic drugs and successfully permeate cellScheme 1. Synthesis of monomer 3 (step 1) membranes (Yildiz et al., 2011). The random co-polymer consists of
hydrophilic (PEG) and hydrophobic counterparts (decyl chain)
(Scheme 1). We have formulated this neutral co-polymer
into a polymersomal drug delivery system (Ps DDS) capable of
encapsulating Fitc-CM-Dextran (MW 4 KDa) with high efﬁciency
as well as having the ability to ‘ﬁne tune’ the diameter of the
vehicle as required. Fitc-CM-Dextran has been utilised as a
surrogate for siRNA as it is an anionic ﬂuorescent dextran that
can be used as a biological mimic, due to its high molecular
weight and hydrophilicity. When tested in Hela cells the Ps
showed a 4-fold increase in uptake of Fitc-CM-Dextran compared
to cells treated with Fitc-CM-Dextran alone.
2. Materials and methods
2.1. Materials and reagents
Chemicals were purchased from commercial sources at the
highest possible purity and used as received. Poly(ethylene glycol)and production of co polymer 5 (step 2).
Fig. 2. 1H NMR spectra of decyl methacrylate monomer 3 (shown in inset) in deuterated chloroform.
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methyl-dextran (Fitc-CM-Dextran) (Mn 4 KDa), methacrylic acid
(99%) and 1-decanol (99%) were purchased form Sigma–Aldrich.
2.2. Synthesis of monomer 3
Monomer 3 was synthesised following a previously published
method (Yildiz et al., 2011). Brieﬂy a solution of N-N-dicyclohex-
ylcarbodiimide (DCC) (4.6 g, 22 mmol) in dichloromethane
(CH2Cl2)(20 ml) was added drop wise over 20 min to a solution
of 1-decanol (1)(3 g, 19 mmol), 4-dimethylaminopyridine (DMAP)
(464 mg, 3.8 mmol) and methacrylic acid (2)(1.6 g, 18.6 mmol) in
CH2Cl2 (60 ml). The reaction was maintained at 0 C for 24 h under
nitrogen. The resulting precipitate was ﬁltered and dried under
reduced pressure. The residue was puriﬁed by column
chromatography; chloroform: methanol (19:1). The methacrylate
monomer (3) was collected as a colourless oil with a slight
yellowy tinge (2.5 g, 59.4%).
2.3. Synthesis of co-polymer 5
Methacrylate monomer (292 mg, 1.3 mmol)(3) and poly(ethyl-
ene glycol) methacrylate (500)(1 g, 2 mmol)(4) were added to theFig. 3. 1H NMR spectra of polymer 5 (showreaction vessel in a ratio of (3:5), along with 5 mg (0.03 mmol) of
free radical generator AIBN and dissolved in a minimal amount of
dry tetrahydrofuran (THF). After three consecutive freeze-pump-
thaw cycles the reaction vessel was sealed under vacuum at 80 C
for 72 h. THF (20 ml) and hexane (20 ml) were added and the
contents centrifuged 3 times at 6000 rpm for 5 min and the
supernatant discarded.
The resulting pellet was dried under reduced pressure by
solvent evaporation to leave amphiphilic co-polymer 5 as an oil.
2.4. Preparation of polymersome (Ps)
Polymersomes were prepared by creating a thin ﬁlm with
1.0 mg co polymer 5 (phase 1) and adding 100 ml 2.5 mg/ml
Fitc-CM-Dextran in phosphate buffered saline (PBS). The
mixture was evaporated to dryness, purged with compressed
air for 30 s, before being suspended in 1.5 ml dry chloroform.
A further 2 ml 1.25 mg/ml polymer in PBS (phase 2) was added
and the solution sonicated using a Branson 3510 bath sonicator
(230 V) at room temperature for 2 min. The organic solvent
was removed from the emulsion under reduced pressure at 40 C.
The polymersomes were lyophilised and stored for use when
required.n in inset) in deuterated chloroform.
Table 1
Integration of speciﬁed peaks in Fig. 2.
Spectral position (ppm) Integration Assigned H
0.9 11.25 5
1.20–1.35 52.14 5
1.60–1.70 7.66 4
1.95 1.92 3
4.15 7.38 2
5.5 3.66 1
6.1 3.61 1
Table 2
Integration of speciﬁed peaks in Fig. 3.
Spectral position (ppm) Integration Assigned H
0.8–0.9 6.39 3
1.20–1.4 10.72 2
3.45–3.95 42.99 1
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2.5.1. Nuclear magnetic resonance (NMR)
1H NMR spectroscopy was carried out on both the synthesised
monomer 3 and the copolymer 5. Samples were prepared using
10 mg of sample dissolved in 1 ml of deuterated chloroform and
analysed using a Varian 500 MHz instrument.
2.5.2. Fourier transform infrared (FTIR)
FTIR was carried out on the synthesised polymer. Samples were
prepared by creating a thin ﬁlm of the polymer between two glass
discs. Spectra were collected on a Perkin Elmer Spectrum
RX1 spectrometer.
2.5.3. Scanning electron microscopy (SEM)
SEM images were carried out by applying a small amount of the
polymersome onto an aluminium stub. The sample was then
lyophilised for 5 h before being sputter coated with gold and
palladium. The images were recorded using a FEI Quanta SEM
under a high vacuum in secondary electron mode.
2.5.4. Encapsulation efﬁciency
Encapsulation efﬁciency was determined by preparing poly-
mersomes by the method described above and varying the amount
of Fitc-CM-Dextran (4 KDa) available for encapsulation. 10 ml
samples of the Ps containing varying amounts of Fitc-CM-Dextran
were then dialysed in 500 ml PBS overnight using a semi-
permeable membrane (MWCO 12–14 KDa). The samples were
analysed using a Varian Cary Eclipse ﬂuorescence spectrometer
using 1 cm quartz cells with an excitation wavelength of 490 nm,
slit width of 5 nm and collecting the emission between 520 and
620 nm. A standard calibration graph was prepared with theFig. 4. Scanning electron microscope images of the formed polymersomes with magniﬁc
of some polymersomes 461.9, 458.1, 613.9 and 538.3 nm in a clockwise fashion from thequation of the line:
y ¼ 22020x
where y = spectral area between 510 and 700 nm and x = concen-
tration of Fitc-CM-Dextran (mM).
The % encapsulation efﬁciency was determined from the
following equation:
FDIntensity
FOintensity
 100%
where FD = ﬂuorescence intensity of Fitc-CM-Dextran following
18 h dialysis and FI = ﬂuorescence intensity of Fitc-CM-Dextran
added.
2.5.5. Drug release study
Release experiments were conducted using the dialysis tubing
method; brieﬂy a 5 ml suspension of polymersome containing
0.1875 mg (46.9 nmol) Fitc-CM-Dextran was sealed in a semi-
permeable membrane (MWCO 12–14 kDa). The tubing was
immersed in 200 ml PBS solution at pH 7.4, with stirring. Samples
were removed at 0, 0.5, 1, 1.5, 2, 2.5, 3, 3.5 and 4 h with all samples
being replaced back into the buffer solution. The amount of
Fitc-CM-Dextran released was analysed using a Varian Eclipse
ﬂuorescent spectrometer using a 1 cm quartz cell, with ﬂuores-
cence measured between wavelengths of 520–620 nm. The
concentration of Fitc-CM-Dextran (mg) present in solution was
analysed from the standard curve equation above, and the % release
determined using the original amount of Fitc-CM-Dextran added
to the dialysis bag.
2.5.6. Cytotoxicity study
Hela cells were seeded at a density of 5 104 cells/ml (100 ml) per
well into a 96 well and incubated at 37 C, 5% CO2, 20% O2 overnight
using Hams-F12 supplemented media. Following adherence, fresh
media was applied to each well (160 ml) with varying concentrations
of polymersome in 40 ml sterile PBS. The cells were then incubated
for a further 24 h before being washed twice with PBS, treated
with MTTsolution (5 mg/ml serum free media) and incubated for 3 h.
The purple blue formazan crystals were dissolved by the addition
of dimethylsulfoxide (DMSO) and the absorbance read at 570 nm
using a BMG labtech Omega microplate.
2.5.7. Dynamic light scattering (DLS), polydispersity index (PDI) and
zeta potential (ZP)
The polymersome solutions were suitably diluted to analyse the
particle size distribution and polydispersity index using dynamic
light scattering (DLS) method. The samples were diluted using
sterile PBS and all measurements taken at room temperature on a
Malvern Nano-ZS zetasizer. The hydrodynamic diameter is quoted
as size  standard error of the mean (n = 3). The polydispersity
index is quoted as PDI  standard deviation (n = 3). The zetaations of 12,000, 24,000 and 50,000 in images A–C respectively. C displays the sizes
e top.
Fig. 5. Hydrodynamic diameter with varying amounts of co-polymer used in formulation steps.
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temperature in PBS using disposable folded capillary cells and
quoted as ZP  standard deviation (n = 3).
2.5.8. Bioimaging
Hela cells were seeded at a density of 5 104 cells/ml (500 ml)
onto a 2 cm2 glass cover slip and incubated at 37 C, 5% CO2, 20% O2
overnight using Hams-F12 supplemented media. Following
adherence, fresh media was applied to the cells (400 ml) and
either 20 ml 2.5 mg/ml Fitc-CM-Dextran (4 KDa) and 80 ml PBS
(control) or 100 ml Liposome containing 0.05 mg Fitc-Dextran
(4 KDa) in PBS. The cells were incubated in the environment
described for a further 5.5 h before being washed twice with 1 ml
PBS and imaged using a Leica SP5Confocal Microscope with an
excitation wavelength of 488 nm and emission collected between
510 and 620 nm.
2.5.9. In-vitro quantiﬁcation study
Hela cells were seeded at a density of 5 104 cells/ml (100 ml)
per well into a 96 well and incubated at 37 C, 5% CO2, 20% O2
overnight using Hams-F12 supplemented media. Following
adherence, fresh media was applied to each well (160 ml) with
either 8 ml 2.5 mg/ml Fitc-CM-Dextran and 32 ml PBS or 40 ml Ps
containing 0.02 mg Fitc-dextran with the control cells containing
160 ml media and 40 ml PBS. The cells were then incubated in the
conditions described for a further 5.5 h before being washing twice
with PBS and the emission read using a BMG labtech Omega
microplate with an excitation wavelength of 485 and emission
collected at 520 nm.
3. Results and discussion
The synthesis of monomer 3 and co-polymer 5 were prepared
as previously described (Yildiz et al., 2011) and the structures
conﬁrmed by 1H NMR spectroscopy (Figs. 2 and 3, respectively).
The following chemical shifts were identiﬁed for monomer 3, asTable 3
Encapsulation efﬁciency with % loading of polymersome with Fitc-CM-
Amou1.5–1.6nt Fitc-CM-Dextran (mg) Load
0.125 3.5 
0.25 6.7 
0.375 9.7 
0.5 12.5 
0.75 17.6 listed with integrations in Table 1,: 1H NMR (CDCl3): d = 0.90 (3H, t,
13 Hz), 1.20–1.35 (14H, m), 1.60–1.70 (2H, m), 1.95 (3H, s), 4.15 (2H,
t, 13 Hz), 5.5 (1H, s), 6.1 (1H, s) the m/z peak was found to be
228 which corresponds to M + 1. The corresponding chemical shifts
for the protons in polymer 5 were found to be: 1H NMR (CDCl3):
d = 0.8–0.89 (3H, bs), 0.9–1.20 (4H, m), 1.20–1.40 (14H, m); 1.50–
1.60 (2H, m), 1.7–2.05 (6H, m), 3.45–3.95 (42H, m), 4.2–4.3 (4H, m).
The oleﬁnic protons present in 3 (Fig. 2) at 5.5 and 6.1 ppm were
absent in the spectrum of 5 (Fig. 3) indicating effective
polymerisation between the two monomers resulting in the
formation of the new carbon carbon sigma bond. The polymerisa-
tion was carried out in a 3:5 molar ratio of hydrophobic:
hydrophilic monomers. This ratio is corroborated when consider-
ing the integration values of speciﬁc known monomer peaks,
Table 2. From Fig. 2 we have established that the majority of the
aliphatic protons of the carbon 10 chain are found between 1.2 and
1.4 ppm. In contrast to this the vast majority of protons from the
poly(ethylene) glycol monomer can be found downﬁeld between
3.45 and 3.95 ppm. If we consider the alkyl chain to have
16 attributed protons (to allow for the shielding and de-shielding
effects seem from the methyl and adjacent ester groups
respectively) then the polymer shown in Fig. 3 should show an
integration value that can be credited to 48 protons (16  3) at
1.2–1.4 ppm. Similarly for the PEG monomer, if we consider that
the average molecular weight of the monomer is 500 Da, this
corresponds to 11 repeat units, as with the alkyl chain if we allow
for the de-shielding effect seen from the ﬁrst and last units, then
we can attribute the integration of the peak between 3.45 and
3.95 ppm to be as a result of 200 protons (40  5). The integration
of the corresponding protons from both monomers is shown in
Fig. 2, it corroborates well with the anticipated 40:200 proton ratio
from the hydrophobic:hydrophilic monomers.
The FTIR spectra displayed the following peaks; 3473.8 cm1
sharp peak attributed to the O—H stretch of the alcohol group on
the poly(ethylene glycol) monomer, 2919.5 cm1 medium strong
peak attributed to the alkyl C—H 1726.3 cm1 a very strong peakDextran.
ing (% wt/wt) % Encapsulation efﬁciency
70.3  1.2
72.2  3.7
69.6  0.1
53.0  2.9
53.2  0.3
Fig. 6. Release proﬁle of the Fitc-CM-Dextran from the polymersome encapsulated within a semi permeable membrane.
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1384.1 cm1 a medium peak depicting a methyl group bend;
1247.8 cm1 which is attributed to the C—O stretch from the ester
group and ﬁnally a broad strong peak is seen between 1200 and
1000 cm1 which can be attributed to the C—O stretch of the ether
groups on the poly(ethylene glycol). As was observed from the
NMR data, the spectral vibrations attributed to the C¼C groups is
absent. The FTIR data further conﬁrms the production of the
polymer. This polymer has been used previously for the delivery
of hydrophobic compounds as it spontaneously forms micellar
structures with a hydrophobic core which we have shown to be
both biocompatible and capable of cellular delivery (Fowley et al.,
2012; Swaminathan et al., 2014).
The polymersomes were characterised for size using both DLS
and SEM while surface charge was determined from zeta
potential measurements. The polydisperisty index (PDI) for each
polymersome was also recorded. Fig. 4a–c displays the SEM
images received with magniﬁcation increasing from left to right.
The spherical shape of the polymersomes was conﬁrmed and
the sizes determined from the microscope were comparable to
those achieved using DLS (Fig. 5) when comparing the same
amounts of polymer added in each phase (as described in
Section 2.5.3). From the SEM image (Fig. 4c) the diameters of a
selection of polymersomes were determined and the sizes rangedFig. 7. MTT cell viability study with varying concentrationbetween 458 and 620 nm. Not surprisingly this size range is
signiﬁcantly larger than the corresponding micelles formed from
the same amphiphilic co-polymer which was in the order of
20 nm, due to the introduction of the hydrophobic bilayer within
the Ps structure. The PDI recorded for each polymersome was
found to be between 0.1 and 0.5, indicating appropriate
polydispersity of the suspension. The zeta potential was
determined as 0.095  0.037 mV indicating charge neutral
polymersomes as anticipated
The encapsulation efﬁciency of the Ps was determined with
varying amounts of Fitc-CM-Dextran, Table 3. The maximum
efﬁciency of 72% was observed for loading at 6.67% wt:wt (wt of
ﬂuorophore:total DDS wt). The Ps was capable of incorporating
larger amounts of Fitc-CM-Dextran, however when the % loading
exceeded 10% wt:wt the encapsulation efﬁciency dropped rather
signiﬁcantly to 53%.
The ability of the polymersome to release its content was
analysed as described in Section 2.5.5. The release proﬁle is shown
in Fig. 5. After a period of 4 h, the polymersome had released 16% of
its cargo, this experiment was not carried out under sink
conditions and therefore it would be expected that under sink
conditions the contents of the DDS may be released sooner,
however it is clear from this study that the polymersome does
indeed release its contents by osmosis.s of polymersome incubated with Hela cells for 24 h.
Fig. 8. A and B, Phase contrast and ﬂuorescence images of Hela cells incubated with 0.05 mg Fitc-CM-Dextran (4 KDa) for 5.5 h. C and D, Phase contrast and ﬂuorescence
images of Hela cells incubated for 5.5 h with 0.05 mg Fitc-CM-Dextran encapsulated within Ps.
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varying the concentrations of polymer is shown in Fig. 6. There are
numerous examples in the literature where the size of the
polymersome have been varied through the incorporation of
different polymers (Nahire et al., 2014; Johnston et al., 2010). The
reason for these differences is due to the variability in interdigita-
tion of the bilayer (Battaglia and Ryan, 2005) and can be modulated
by changing the nature of the hydrophobic entities in the
amphiphilic polymer or the chemical environment used to
produce the polymersomes (Wachtel et al., 2013). Here we reveal
a signiﬁcant degree of control in the size of the polymersome
simply by varying the amounts of co-polymer used during
production. It can be seen from Fig. 6 that by varying the amount
of co-polymer added in phase 1 of the production we can controlFig. 9. Percentage uptake of both free Fitc-CM-Dextran and encapsulated Ps- Fitc-CM-the diameter of the Ps. We have shown that by varying the amount
of co-polymer added in phase 1 from 0.25 mg to 0.5 mg, while
keeping the ratio of co-polymer added in phase 2 constant at 1:5,
an increase in diameter from 284 nm to 364 nm was observed, the
PDI recorded for each is these samples was 0.36  0.01 and
0.36  0.02 respectively, indicting a good uniformity in polydis-
persity. Similarly if the amount of co-polymer added in phase 1 of
the production was increased to 1.25 mg, with again a 1:5 ratio of
co-polymer added in phase 2, the hydrodynamic diameter of the Ps
increases to 539 nm (PDI 0.35  0.05). A similar trend was evident
when the Ps was prepared using a 1:2.5 ratio of co-polymer
between phase 1 and 2 with the polydispersity index ranging from
0.22 to 0.28, again indicative of good polydispersity. These results
suggest that the ability to control the size of the Ps is primarily dueDextran based on the original amount of drug added. Incubated at 37 C for 5.5 h.
8 C. Martin et al. / International Journal of Pharmaceutics 481 (2015) 1–8to the amount of co-polymer used in the production of the inverted
micelle (phase 1). However when the amount of co-polymer added
in phase 1 exceeds 2.5 mg/ml no signiﬁcant increase in Ps diameter
was observed.
In order to establish the biocompatibility of this new drug
delivery system it was analysed for cytotoxicity in Hela cells using
the MTT viability assay. The results shown in Fig. 7 reveal that the
system is not toxic to Hela cells in a concentration up to 0.3 mg/ml
with an approximate LD50 of 1.25 mg/ml. This value was higher
than that determined when the same polymer was assembled
into micelles (Yildiz et al., 2011), one possible explanation for this
could lie with the increased size of the Ps when compared to the
micelle, however the toxicity is well within the range which
would be deemed appropriate for use (Rad et al., 2014). The
ability of the Ps to cross the cell membrane was investigated using
the photochemical properties of the biological mimic Fitc-CM-
Dextran by incubating either the free chromophore or the
encapsulated chromophore in Hela cells. It can be seen from
the confocal images displayed in Fig. 8 that the Ps encapsulated
Fitc-CM-Dextran was in deed capable of crossing the cell
membrane. The punctate nature of the image would suggest
that the DDS is accumulating within the lysosome. There was a
signiﬁcant increase in the amount of ﬂuorescence generated from
the Fitc-CM-Dextran when encapsulated within the Ps when
compared to the same amount of free Fitc-CM-Dextran, as evident
from both the phase contrast images A and C and the ﬂuorescence
images B and D. Both C and D have an increased intensity of
ﬂuorescence emission when excited at 488 nm. This enhance-
ment was quantiﬁed using a plate reader with a 4-fold increase in
the uptake of encapsulated Fitc-CM-Dextran when compared to
free Fitc-CM-Dextran (Fig. 9).
4. Conclusions
We have successfully prepared a neutral random co-polymer
capable of forming polymersomes and enhancing the delivery of a
high molecular weight, negatively charged molecule. The polymer-
some enhanced the delivery of Fitc-CM-Dextran to Hela cells 4-
fold. This is the ﬁrst time a co-polymer such as this has been
formulated into a bilayered sytem with an aqueous core. The
potential to tailor the speciﬁc size of the nanoparticle and the facile
synthetic procedure to create these supramolecular structures
means it could be tailored to suit various biological therapies. In
the future polymersomes such as these could be further adapted to
increase capacity and site speciﬁc delivery. The relatively low
cellular uptake could be enhanced with the introduction of
cholesterol into the bilayered system of the DDS (He et al., 2014).
The addition of site speciﬁc receptors for targeting and enhanced
cellular uptake could also increase cell speciﬁcity and uptake.
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